Financial Performance - The group's unaudited revenue for the nine months ended September 30, 2020, was approximately SGD 4,826,000, a decrease of about SGD 600,000 or 11.1% compared to SGD 5,426,000 for the same period in 2019[4] - The group reported an unaudited loss of approximately SGD 955,000 for the nine months ended September 30, 2020, a decrease of SGD 1,648,000 or 237.8% compared to a profit of SGD 693,000 for the same period in 2019[4] - The loss per share for the nine months ended September 30, 2020, was (0.16) Singapore cents, compared to earnings of 0.12 Singapore cents for the same period in 2019[4] - The group's total comprehensive loss for the nine months ended September 30, 2020, was SGD 980,000, compared to total comprehensive income of SGD 693,000 for the same period in 2019[6] - The company reported a loss attributable to owners of SGD 955,000 for the nine months ended September 30, 2020, compared to a profit of SGD 693,000 for the same period in 2019, resulting in a loss per share of SGD 0.16[53] - The company reported a loss from joint ventures of SGD 709,000 for the nine months ended September 30, 2020[55] - The company recorded a loss of approximately SGD 955,000 for the nine months ended September 30, 2020, a decrease of about SGD 1,648,000 or 237.8% compared to a profit of SGD 693,000 for the same period in 2019[79] Revenue Breakdown - Total revenue for the nine months ended September 30, 2020, was SGD 4,826,000, a decrease from SGD 5,426,000 in the same period of 2019, representing a decline of approximately 11%[44] - Revenue from consultation services was SGD 980,000, while prescription and dispensing services generated SGD 1,487,000, and treatment services brought in SGD 1,400,000 for the nine months ended September 30, 2020[44] - The company experienced a decrease in revenue from consultation services, which accounted for 20.3% of total revenue in 2020, down from 26.3% in 2019[60] Expenses and Costs - Employee benefit expenses for the nine months ended September 30, 2020, were SGD 1,748,000, compared to SGD 1,504,000 for the same period in 2019[6] - The cost of consumables and medical supplies for the nine months ended September 30, 2020, was SGD 759,000, compared to SGD 839,000 for the same period in 2019[62] - Professional and consulting fees surged to SGD 2,586,000 for the nine months ended September 30, 2020, compared to SGD 755,000 in the previous year[50] - Other operating expenses surged by 130.0% to SGD 3,450,000 for the nine months ended September 30, 2020, from SGD 1,500,000 in the previous year[71] - Employee benefits expenses increased to SGD 1,748,000 for the nine months ended September 30, 2020, up from SGD 1,504,000 for the same period in 2019, representing a growth of approximately 16.2%[65] Corporate Governance and Compliance - The company confirmed compliance with all applicable corporate governance code provisions for the nine months ended September 30, 2020[88] - The audit committee reviewed the unaudited condensed consolidated financial statements for the nine months ended September 30, 2020[101] - The company appointed a new independent non-executive director on June 8, 2020, ensuring compliance with GEM listing rules[87] - The company has maintained a high standard of corporate governance to manage business risks and enhance transparency[87] - The company has adopted a code of conduct for securities transactions by directors, confirming compliance throughout the reporting period[92] Future Outlook - The company expects revenue to continue to recover for the remainder of the year as Singapore's economy reopens and new operations in Hong Kong begin to contribute to revenue[58] - The company plans to continue developing and launching its own skincare products and nutritional supplements for sale in its clinics and directly to the public[58] - The company plans to expand its multi-specialty center focused on dermatology, aesthetics, preventive and regenerative medicine, and obstetrics and gynecology services in Hong Kong[75] Other Financial Information - The company incurred finance costs of SGD 31,000 for the nine months ended September 30, 2020, compared to no finance costs for the same period in 2019[6] - Interest income from financing leases was SGD 31,000, while interest income from other sources was SGD 348,000 in the previous year[46] - Lease liability interest expenses increased to SGD 134,000 for the nine months ended September 30, 2020, compared to SGD 61,000 in the same period of 2019[48] - Income tax expenses decreased to approximately SGD 166,000 for the nine months ended September 30, 2020, down from SGD 210,000 in the previous year, attributed to a pre-tax loss of approximately SGD 789,000[78]
德斯控股(08437) - 2020 Q3 - 季度财报